March 27, 2018 / 11:41 AM / 3 months ago

BRIEF-Arrowhead Pharmaceuticals Arrowhead Begins Dosing In Phase 1/2 Study Of ARO-HBV

Reuters Staff

1 Min Read

March 27 (Reuters) - Arrowhead Pharmaceuticals Inc:

* ARROWHEAD BEGINS DOSING IN PHASE 1/2 STUDY OF ARO-HBV FOR TREATMENT OF CHRONIC HEPATITIS B Source text for Eikon: Further company coverage: (Reuters.Brief@thomsonreuters.com)

Our Standards:The Thomson Reuters Trust Principles.

0 : 0

narrow-browser-and-phone
medium-browser-and-portrait-tablet
landscape-tablet
medium-wide-browser
wide-browser-and-larger
medium-browser-and-landscape-tablet
medium-wide-browser-and-larger
above-phone
portrait-tablet-and-above
above-portrait-tablet
landscape-tablet-and-above
landscape-tablet-and-medium-wide-browser
portrait-tablet-and-below
landscape-tablet-and-below